OR WAIT null SECS
New products and services from TERUMO Medical Corp., TOLMAR Pharmaceuticals, Spry Publishing, and Beckman Coulter Diagnostics.
Somerset, NJ-The GLIDEWAY ureteral access sheath is the latest addition to the GLIDEWAY access sheath portfolio used in minimally invasive procedures such as ureteroscopy and percutaneous nephrolithotomy. The ureteral access sheath has a precision linear tip design with “ultra-smooth transitions engineered to optimize day-to-day urologic access needs,” according to TERUMO Medical Corp., the sheath’s manufacturer. The GLIDEWAY ureteral access sheath was recently introduced at the AUA annual meeting in Orlando, FL.
For more information, visit www.terumomedical.com.
Lincolnshire, IL-TOLMAR Pharmaceuticals, Inc. now holds exclusive distribution rights to market leuprolide acetate for injectable suspension (ELIGARD) in the United States and Puerto Rico. Leuprolide acetate for injectable suspension is a prescription medication for the palliative treatment of advanced prostate cancer. The gonadotropin-releasing hormone agonist launched in the U.S. in 2002.
For more information, visit www.tolmar.com.
Ann Arbor, MI-“Survivorship: Living Well During and After Cancer” provides up-to-date, evidence-based guidance and information from Barrie Cassileth, MS, PhD, founder of the Integrative Medicine Service at Memorial Sloan Kettering Cancer Center, New York. In the book, Dr. Cassileth helps patients understand the latest research results and identify complementary therapies that may be appropriate to relieve their individual symptoms. From yoga and acupuncture to massage and mind/body therapies, she provides reliable resources and cautions patients on how to avoid quackery and other obstacles that may prevent successful cancer treatment, according to Spry Publishing.
For more information, visit www.sprypub.com.
Brea, CA-The Prostate Health Index (phi) is a simple, noninvasive blood test that developer Beckman Coulter Diagnostics says is three times more specific in detecting prostate cancer than the PSA test. The phi’s accuracy decreases the need for many men who test positive for elevated PSA levels to undergo a biopsy in order to achieve a reliable diagnosis. The test helps physicians distinguish prostate cancer from benign conditions by using three different markers-PSA, freePSA, and p2PSA-in men with an elevated PSA. The phi is now available to physicians nationwide through Innovative Diagnostics Laboratory, a national clinical reference laboratory.
For more information, visit www.beckmancoulter.com.
Subscribe to Urology Times to get monthly news from the leading news source for urologists.